Physician profile
Emil Lesho
NPI 1982622536
$67,646.58
in general payments reported to CMS, 2019-2025
7 companies · $13K in 2025
The $13K reported for 2025 was more than what 94% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $5,499 · 2021: $2,152 · 2022: $4,294 · 2023: $14K · 2024: $14K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Consulting Fee: $2,390 · Travel and Lodging: $1,345 · Food and Beverage: $1,047 · Education: $755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,078.39 |
| Consulting Fee | $2,390.00 |
| Travel and Lodging | $1,345.30 |
| Food and Beverage | $1,046.66 |
| Education | $754.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22,849.21 | 2022-2025 | |
| Astellas Pharma US INC | $22,171.11 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $19,054.32 | 2023-2024 | Rebyota |
| Melinta Therapeutics, LLC | $3,519.68 | 2019-2023 | Vabomere, Kimyrsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.66 | 2019 | |
| Biomerieux INC | $12.90 | 2023 | |
| Merck Sharp & Dohme LLC | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emil Lesho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.